Routine use of gemtuzumab ozogamicin in 7+3-based inductions for all 'non-adverse' risk AML

Abdullah Ladha,Gavin Hui,Edna Cheung,Caroline Berube,Steven E. Coutre,Jason Gotlib,Michaela Liedtke,Tian Y. Zhang,Lori Muffly,Gabriel N. Mannis

BLOOD（2021）

引用 3|浏览52

暂无评分

摘要

Gemtuzumab ozogamicin (GO) is an antibody–drug conjugate (ADC) linking a semi-synthetic derivative of calicheamicin, a DNA damage-inducing agent, to a humanized monoclonal antibody specific for CD3...

查看译文

关键词

gemtuzumab ozogamicin,non-adverse

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要